--- title: "Nanjing Pharmaceutical: Baiyunshan's subsidiary Guangyao Phase II Fund intends to acquire 145 million shares of the company" type: "News" locale: "en" url: "https://longbridge.com/en/news/259199729.md" description: "NPC has signed a strategic investment agreement with BAIYUNSHAN PH and Guangzhou Pharmaceutical Phase II Fund, under which the Guangzhou Pharmaceutical Phase II Fund intends to acquire 145 million shares of NPC, accounting for 11.04% of the total share capital. Both parties will jointly formulate market expansion plans, optimize the supply chain, enhance industrial chain cooperation, promote the transformation and upgrading of the traditional Chinese medicine industry, build a modern circulation system for Chinese medicinal materials, and promote traditional Chinese medicine culture" datetime: "2025-09-28T08:50:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/259199729.md) - [en](https://longbridge.com/en/news/259199729.md) - [zh-HK](https://longbridge.com/zh-HK/news/259199729.md) --- # Nanjing Pharmaceutical: Baiyunshan's subsidiary Guangyao Phase II Fund intends to acquire 145 million shares of the company According to the announcement from Nanjing Pharmaceutical (600713.SH), the company has signed a "Strategic Investment Agreement" with Baiyunshan (600332.SH) and Guangzhou Guangyao Phase II Fund Equity Investment Partnership (Limited Partnership) (referred to as "Guangyao Phase II Fund"). Baiyunshan's subsidiary Guangyao Phase II Fund intends to invest in and acquire all 145 million shares held by the company's current second-largest shareholder, Alliance Healthcare Asia Pacific Limited, which accounts for 11.04% of the company's total share capital as of the date of the agreement. According to the agreement, the company plans to actively develop market expansion and channel sharing plans with Baiyunshan, integrate and optimize supply chain resources and logistics distribution networks, and establish a stable and efficient supply chain system; for its own industrial products, the company will implement effective mechanisms for market access and channel sales, mutually enhancing the cooperation level of the industrial chain, focusing on the efficiency of the main business, and strengthening the competitiveness of both parties' listed company products and services. The company and Baiyunshan will actively support the cooperation of their respective subsidiaries in traditional Chinese medicine to promote the transformation and upgrading of the traditional Chinese medicine industry, accelerate the standardization and modernization of traditional Chinese medicine production processes and workflows; collaboratively build a modern traditional Chinese medicine circulation system, establish a full-chain traceability system for traditional Chinese medicinal materials from planting, processing to sales, vigorously promote traditional Chinese medicine culture, and strengthen and expand the traditional Chinese medicine cultural industry ### Related Stocks - [600713.CN](https://longbridge.com/en/quote/600713.CN.md) - [600332.CN](https://longbridge.com/en/quote/600332.CN.md) - [00874.HK](https://longbridge.com/en/quote/00874.HK.md) ## Related News & Research - [Can the business model of operators launching AI token packages be viable?](https://longbridge.com/en/news/286700860.md) - [Palm Launches The Onboard Suite: Real-Time Access to 125 Million Businesses Across 150,000 Jurisdictions](https://longbridge.com/en/news/287063783.md) - [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md) - [Singapore’s Fairprice Xtra to launch $66 all-you-can-eat durian buffet featuring Musang King, Black Thorn](https://longbridge.com/en/news/286881811.md) - [](https://longbridge.com/en/news/286948461.md)